Literature DB >> 16557685

In Vivo Susceptibility of Cryptococcus neoformans to Hamycin, Amphotericin B, and 5-Fluorocytosine.

S Shadomy1, H J Shadomy, J P Utz.   

Abstract

Previous investigations have shown that hamycin is 5 to 10 times more active in vitro than amphotericin B against Cryptococcus neoformans, whereas 5-fluorocytosine is approximately 15 times less active. Present studies are concerned with a comparison of these drugs in vivo. Three strains of C. neoformans which varied in both their virulence for mice and their susceptibilities to the antifungal agents were studied. Acute experimental infections were established in mice by using inocula containing approximately 4 x 10(6) cells. The mice were treated by gastric intubation for 28 days; daily dosages of the three drugs ranged from 12.5 to 250 mg/kg. The polyenes were suspended in 5% dimethyl sulfoxide, whereas 5-fluorocytosine was suspended in saline. Amphotericin B was the most effective drug, with almost complete absence of toxic deaths in control mice and increased survival in mice infected with two of the three strains and treated with 25 mg/kg per day or more. 5-Fluorocytosine was nontoxic but provided protection against only one strain. Hamycin was both the least effective and the most toxic compound, providing only slight protection at doses of 12.5 or 25 mg/kg per day and causing toxic deaths in over 50% of uninfected mice at doses above 25 mg/kg per day.

Entities:  

Year:  1970        PMID: 16557685      PMCID: PMC415864          DOI: 10.1128/iai.1.1.128-134.1970

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  9 in total

1.  IN VIVO ACTIVITY OF COLLOIDAL HAMYCIN, AN ANTIFUNGAL ANTIBOTIC.

Authors:  J E BENNETT; T W WILLIAMS; W PIGGOTT; C W EMMONS
Journal:  Proc Soc Exp Biol Med       Date:  1964-10

2.  5-Fluorocytosine in human cryptococcosis.

Authors:  J P Utz; B S Tynes; H J Shadomy; R J Duma; M M Kannan; K N Mason
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

3.  In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine.

Authors:  S Shadomy; H J Shadomy; J A McCay; J P Utz
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

4.  Clinical and laboratory studies of a new micronized preparation of hamycin in systemic mycoses in man.

Authors:  J P Utz; H J Shadomy; S Shadomy
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

5.  Bioassay for hamycin and amphotericin B in serum and other biological fluids.

Authors:  S Shadomy; J A McCay; S I Schwartz
Journal:  Appl Microbiol       Date:  1969-04

6.  In vitro and in vivo activity of hamycin against Blastomyces dermatitidis.

Authors:  S Shadomy; G M Robertson; H J Shadomy; J P Utz; E Gamble
Journal:  J Bacteriol       Date:  1969-02       Impact factor: 3.490

7.  In vitro studies with 5-fluorocytosine.

Authors:  S Shadomy
Journal:  Appl Microbiol       Date:  1969-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.